Why people care.
What the evidence shows.
A source-linked guide to why these peptides attract attention, what human evidence exists, and how their regulatory status is changing.
Interest area describes the conversation around a peptide. It is not an approved indication, a benefit claim, or a recommendation to use it.
Recovery & repair
The magnetic center of peptide culture: faster healing, tissue repair, muscle, and getting back sooner.
BPC-157
BPC-157 has become a shorthand for faster recovery in peptide culture, with conversation spanning tendons, joints, and the gut.
Huge attention. Thin clinical footing.
TB-500
TB-500 is discussed as a recovery and tissue-repair compound, especially in athletic and post-injury communities.
Popular recovery narrative. Preclinical center of gravity.
PEG-MGF
PEG-MGF is discussed around muscle growth, training adaptation, and recovery—high-interest territory for performance audiences.
Performance appeal; evidence review pending.
Metabolic & longevity
Peptides discussed for metabolism, aging, sleep, body composition, and longer healthy life.
MOTS-c
As a mitochondrial-derived peptide, MOTS-c sits at the intersection of metabolism, exercise, aging, and body-composition interest.
A big idea waiting on human evidence.
Epitalon
Epitalon attracts longevity and sleep interest because it is often framed around aging biology and circadian function.
Longevity appeal; limited clinical clarity.
AOD-9604
AOD-9604 is widely framed as a fat-loss fragment of human growth hormone without the full hormone's broader effects.
Substantial exposure history. Obesity benefit still unproven.
CJC-1295
CJC-1295 is discussed for growth-hormone release, body composition, recovery, and healthy aging.
Hormone response is real. Clinical benefit and identity transfer are not.
Ipamorelin acetate
Ipamorelin is popular as a supposedly selective growth-hormone secretagogue and is often discussed alongside CJC-1295.
Popular pairing. Negative human efficacy result and FDA safety concern.
Brain & sleep
Peptides discussed for focus, brain recovery, resilience, and sleep—areas where interest often outruns the evidence.
Semax
Semax is one of the most discussed cognitive and neurologic peptides, often associated with focus, resilience, and neuroprotection.
More human history than many peers; still unresolved.
Emideltide / DSIP
DSIP has enduring appeal because sleep is universal and the idea of a sleep-linked peptide is intuitively powerful.
A memorable premise with an unfavorable signal.
Dihexa acetate
Dihexa draws attention from the cognitive-enhancement and neuroregeneration edge of the peptide world.
Futuristic promise; human evidence gap.
Selank acetate
Selank attracts attention as a calming or cognition-adjacent peptide, especially in anxiety and nootropic communities.
Intriguing small study. Thin independent clinical foundation.
Skin & appearance
Peptides with visible, consumer-facing appeal and unusually strong recognition beyond research circles.
GHK-Cu
GHK-Cu already has strong name recognition in skin, hair, and cosmetic-aging conversations.
High consumer familiarity. Context matters.
Melanotan II
Melanotan II is widely recognized for tanning and appearance-related effects, giving it unusually strong consumer awareness.
Visible effects, visible risk signals.
Immune & inflammation
Peptides discussed for immune function, inflammation, wound healing, and tissue repair.
KPV
Interest centers on the idea of a small anti-inflammatory peptide that might influence wound, gut, and skin biology.
Compelling biology; no human exposure identified by FDA.
LL-37
LL-37 is an innate-immune peptide, which puts it in conversations about host defense, inflammation, and tissue repair.
Broad biological interest. Regulatory review ahead.
Thymosin alpha-1
Thymosin alpha-1 has a long research history across immune, infectious-disease, cancer, and critical-care settings.
More human research than most peers. No general immune-benefit conclusion.
Regulatory conclusions should change only when the source record changes.
Peplyst keeps every material step attached to the compound and date it affected.
See the change log →